Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

905) (378,739)

Changes in assets and liabilities:

Prepaid expenses and other

current assets 168,987 270,745

Deposits - 690,000

Accounts payable 204,029 526,711

Accrued expenses 3,465,028 3,811,373

Deferred grant revenue (147,464) -

Other liabilities 86,644 234,833

Net cash used in operating

activities (51,641,258) (51,619,518)

Cash flows from investing activities:

Purchases of property and equipment (279,433) (1,354,156)

Proceeds from sales of property

and equipment 200,179 -

Purchases of marketable securities (138,953,879) (102,232,608)

Proceeds from sales of marketable

securities 3,577,859 82,137,888

Maturities of marketable securities 86,695,000 29,670,000

Net cash provided by (used in)

investing activities (48,760,274) 8,221,124

Cash flows from financing activities:

Principal payments on obligations

under capital lease - (1,540)

Principal payments on note payable - (141,074)

Proceeds from exercise of stock options

and warrants 148,640 127,115

Proceeds from issuance of common stock,

net of issuance costs 111,254,850 53,329,951

Net cash provided by

financing activities 111,403,490 53,314,452

Effect of foreign currency translation (1,320) 22

Net incr
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... London (PRWEB) May 28, 2015 ... Computer Aided Engineering software, announced today it is ... (PSRI). CD-adapco will provide state-of-the-art engineering simulation tools ... share their expertise and experiences in analyzing particle ... industry members and advance the understanding of flow ...
(Date:5/28/2015)... 28, 2015 Global futurist and ... to ask his audiences if they are ready ... robotics, solar cells, fuel cells, rapid health care ... battery storage technology, driverless cars, artificial intelligence masquerading ... inexpensive online education. , While the majority ...
(Date:5/28/2015)... Cambridge, MA (PRWEB) May 28, 2015 ... provider located in Basel, Switzerland, and the ... (ACRES), a Cambridge, Massachusetts-based non-profit organization operating ... building a global system to enhance quality, ... product development and health research, are pleased ...
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) ... Breast Cancer Monoclonal Antibodies Market Outlook 2020" ... seems to dominate the breast cancer monoclonal antibody ... molecule, Herceptin has been able to dominate this ... breast cancer cells become recalcitrant and relapsed condition ...
Breaking Biology Technology:CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3
... GeneGo, Inc., the leading systems biology tools company, ... GeneGo Center of Excellence. Burnham researchers will have ... training and advanced support. The Burnham institute ... OMICs experimental studies throughout many departments, including research ...
... 2 NicOx S.A.,(NYSE Euronext Paris: COX) ... with,DSM for the commercial manufacture and supply ... ingredient). Naproxcinod is NicOx, lead,investigational product and ... (CINOD) class of,anti-inflammatory agents, which recently achieved ...
... 2 Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer ... from severe angina, today announced the addition of veteran medical ... Cohen as a member of the Company,s Board of Directors, ... , Mr. Cohen, 49, has over ...
Cached Biology Technology:The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 3
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/21/2015)... BOSTON , May 21, 2015 ... scientific potential of music for health, today announced a ... (BerkleeICE) . The partnership will center on collaboration on ...  As a first step in the collaboration, The Sync ... course on "Music as Medicine" in the 2015-2016 academic ...
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... ham radio, amateur astronomy, and early computing? Well, ... 2,000 people from around the world belong to the ... fuel cells, low-cost lab equipment, environmental surveillance, personal bio-monitoring, ... Project at the Woodrow Wilson Center is partnering with ...
... a consortium of universities and companies headed by biologists at ... three years to conduct basic research that will pave the ... alternative to gasoline for our nation,s transportation fuel. The ... million from a consortium of biotechnology and energy companies, providing ...
... is available in Spanish . Health conscious ... good choice when it comes to preparing meals and dipping ... the Agricultural Research Service (ARS), has found that phenolic components ... the inflammatory response. The researchers knew from other studies ...
Cached Biology News:DOE awards UC San Diego consortium $9 million for algal biofuels research 2Molecular biology provides clues to health benefits of olive oil 2